Anavex Life Sciences to Present at Upcoming Global Healthcare Conferences

Rhea-AI Summary

Anavex Life Sciences Corp. (Nasdaq: AVXL) announced its CEO, Christopher U. Missling, PhD, will present updates at the Cantor Fitzgerald Global Healthcare Conference on September 17, 2020, and the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020. Anavex is focused on innovative therapies for neurodegenerative disorders, including Alzheimer’s and Parkinson’s diseases. Their lead drug, ANAVEX®2-73 (blarcamesine), has shown promise in clinical trials and aims to restore cellular balance in the brain, allowing hope for future treatment breakthroughs.

NEW YORK, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today announced that its President & Chief Executive Officer, Christopher U. Missling, PhD, will present a company update at both the Cantor Fitzgerald Global Healthcare Conference 2020 and the H.C. Wainwright 22^nd Annual Global Investment Conference. The conferences are both virtual and details of the presentations are below.

• Cantor Global Healthcare Conference 2020
  When: Thursday, September 17^th, 2020 at 12:40 pm ET.
  A live webcast is available at: https://www.webcaster4.com/Webcast/Page/2495/37416.
  
  
• H.C. Wainwright 22nd Annual Global Investment Conference
  When: Monday, September 14^th, 2020 at 12:00 pm ET.
  A live webcast is available to clients of the firm at https://hcwevents.com/.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, pain and various types of cancer. Anavex’s lead drug candidate, ANAVEX®2-73 (blarcamesine), recently completed a successful Phase 2a clinical trial for Alzheimer’s disease. ANAVEX®2-73 (blarcamesine) is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. ANAVEX®2-73 (blarcamesine) also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson’s Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 (blarcamesine) for the treatment of Parkinson’s disease. ANAVEX®3-71, which targets sigma-1 and muscarinic receptors, is a promising preclinical drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer’s disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the company on Twitter, Facebook and LinkedIn.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

For Further Information:

Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: info@anavex.com

Investors & Media:

Email: ir@anavex.com

FAQ

When will Anavex present at the Cantor Fitzgerald Global Healthcare Conference 2020?

Anavex will present on September 17, 2020, at 12:40 pm ET.

What is Anavex's lead drug candidate for Alzheimer's disease?

Anavex's lead drug candidate for Alzheimer's disease is ANAVEX®2-73 (blarcamesine).

What is the focus of Anavex Life Sciences Corp.?

Anavex focuses on developing therapeutics for neurodegenerative and neurodevelopmental disorders.

When will Anavex present at the H.C. Wainwright Global Investment Conference?

Anavex will present on September 14, 2020, at 12:00 pm ET.

What are the potential benefits of ANAVEX®2-73 (blarcamesine)?

ANAVEX®2-73 is designed to restore cellular homeostasis and has shown potential in treating Alzheimer’s disease and other CNS disorders.